Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.52 |
| ▸ | FABP7 | O15540 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21332462 | 0.92 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL8772818 | 0.88 | KMT2A (0.58) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL27892188 | 0.88 | KMT2A (0.58) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL3757636 | 0.86 | KMT2A (0.72) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL28675945 | 0.86 | KMT2A (0.59) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL2411832 | 0.86 | KMT2A (0.63) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL28783421 | 0.85 | KMT2A (0.56) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL4553478 | 0.84 | KMT2A (0.63) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL30238049 | 0.83 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL1800381 | 0.83 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-01 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| CN-105154498-A | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK AS | 2015-12-16 | — | — | CN | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| CN-101910193-A | Semi-recombinant preparation method of GLP-1 analogue | NOVO NORDISK AS | 2010-12-08 | — | — | CN | disclosed |
| US-6252096-B1 | PHOTOAFFINITY PROBE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | KMT2A 3854/4885EPHX2 2825/4885FABP5 2562/4885 |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | ITGB1, ITGAV, ITGA1 | KMT2A 3854/4885EPHX2 2825/4885FABP5 2562/4885 |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | KMT2A 3854/4885EPHX2 2825/4885FABP5 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.